NASD · Healthcare · Medical Devices · USA
10x Genomics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Medical Devices industry.
10x Genomics develops technology platforms that enable researchers to study biology at the cellular and tissue level. The company provides instruments, reagents and analytical software for examining individual cells and spatial organization within tissue samples. Its customers are academic institutions, biopharmaceutical companies and government research organizations operating worldwide.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the 10x Genomics Inc stock.
Overvalued: intrinsic value $3.37 per share, market price $69.89, margin of safety -1972.3% (as of 2026-10-19).
Its liquidation floor, current assets minus every liability, values the shares at $3.37; the price of $69.89 is 1972% above that value.
Leak Score: 35/100 on 9 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
59 more in this industry show a wider margin of safety.
TXG is overvalued (as of the 2026-10-19 close). Its liquidation floor, current assets minus every liability, values the shares at $3.37; the price of $69.89 is 1972% above that value.
$3.37 per share (as of the 2026-10-19 close), against a market price of $69.89. That is a margin of safety of -1972.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
35 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.